Download Programmed Cell Death (Apoptosis) and Cancer Chemotherapy

Willem van de Velde the Younger (Dutch, 1633-1707), A Kaag and Smalschip Near the Stove, 1660.
Programmed Cell Death (Apoptosis) and Cancer Chemotherapy
Samuel R. Denmeade, MD, and John T. Isaacs, PhD
Background: Programmed cell death involves a genetic reprogramming of the cell to promote an energy-dependent cascade of biochemical and
morphological changes within the cell that result in its death and elimination.
Methods: The regulations and mechanisms of programmed cell death are reviewed with an emphasis on how derangement of this mechanism may be
involved in modulating responsiveness to chemotherapy.
Results: Activation of this programmed death process is controlled by a series of endogenous cell-type-specific signals. In addition, a variety of exogenous
cell-damaging treatments (eg, radiation, chemicals, and viruses) and most chemotherapeutic drugs can activate this pathway if sufficient injury to the cell
occurs. Resistance to chemotherapy can involve alterations in the ability of a malignant cell to activate the programmed cell death (apoptotic) pathway
when damaged by these exogenous agents.
Conclusion: The most important determinant of tumor resistance may be a generalized resistance to induction of programmed cell death rather than
resistance based on specific alteration in drug/target interactions.
Introduction
The growth of any tissue, whether normal or malignant, is determined by the quantitative relationship between the rate of cell proliferation and the rate of cell death. In
the adult, these cell kinetic rates are balanced such that neither involution nor overgrowth of tissues normally occurs. Because a cell must undergo a series of molecular
changes to acquire the malignant phenotype and because these changes are often induced by agents or treatments that damage the cell over an extended period of time,
any events that derange this kinetic balance in favor of an enhanced survival of initiated or damaged cells promote the carcinogenic process. In this regard, certain
promoting agents of carcinogenesis function not to enhance proliferation but rather to decrease the death of neoplastic-initiated cells.[1] Thus, understanding what
normally regulates cell death and how this regulation is deranged in carcinogenesis has important ramifications for chemoprevention. Also important for therapy of
established cancers is the realization that a fundamental requirement for full transformation of premalignant cells into cancer cells is that they must undergo a series of
genetic changes that disrupts this homeostatic balance. This disruption allows the rate of proliferation of cancer cells to exceed cell death, resulting in the net continuous
accumulation of malignant cells. It is this continuous net accumulation of malignant cells that produces the lethality of cancer.
A successful therapy for established cancers requires readjusting the quantitative cell kinetic relationship so that cell death exceeds cancer cell proliferation. If this
negative relationship can be maintained, eradication of the cancer is possible and the patient can be cured. However, no therapeutic regimens are presently available to
accomplish this goal repeatedly when used against solid cancers such as breast, prostate, lung, and colon. An understanding of what normally regulates the balance
between cell proliferation and cell death in these tissues is critical to maintain this negative relationship.
Programmed Cell Death (Apoptosis)
Unlike the detailed framework that is rapidly becoming defined in both molecular and cell biological terms for cell proliferation, an understanding of the initiation of cell
death and the cellular mechanics of this process are just beginning. Cell death can involve processes that are equal in complexity and regulation to those involved in cell
proliferation. This knowledge has been appreciated for many years by developmental biologists, who have coined the term "programmed cell death" (PCD) to
distinguish the active, orderly, and cell-typeñspecific death observed in developing organisms from necrotic cell death. Necrotic death is a response to pathologic changes initiated outside of the cell and can be elicited by any of a large series of factors that result in a change in the plasma membrane permeability. This increased
permeability results in cellular edema and in the eventual osmotic lysis of the cell. In necrotic cell death, the cell has a passive role in initiating the process of death. In
PCD, a cell undergoes an energy-dependent process of cellular death initiated by specific signals in an otherwise normal microenvironment. In PCD, the cell is an active
participant in its own demise.[2,3]
PCD is a widespread phenomenon that occurs normally at different stages of morphogenesis, in the growth and development of metazoans, and in normal turnover in
adult tissue.[4] Under these physiologic conditions, PCD is initiated in specific cell types by both endogenous tissue-specific agents (generally hormones or locally
diffusing chemicals) and exogenous, cell-damaging treatments (eg, radiation, chemicals, and viruses). Endogenous activation of PCD occurs either due to the positive
presence of a tissue-specific inducer (eg, glucocorticoids that induce death of immature thymocytes)[5] or due to the negative lack of a tissue-specific survival factor
(eg, androgen ablation that induces death of prostatic glandular cells).[6] Once initiated, PCD leads to a cascade of biochemical and morphological events that result in
irreversible degradation of the genomic DNA and fragmentation of the cell. The morphologic pathway for PCD is stereotypical and has been named "apoptosis" to
distinguish this process from necrotic cell death.[2,3]
Apoptosis was originally defined by Kerr[2] as the orderly and characteristic sequence of structural changes resulting in the programmed death of the cell. The temporal
sequences of events of apoptosis comprise chromatin aggregation, nuclear and cytoplasmic condensation, and eventual fragmentation of the dying cell into a cluster of
membrane-bound segments (apoptotic bodies) that often contain morphologically intact organelles. For example, in apoptosis as opposed to necrotic death,
mitochondria do not swell and lose their function as an early event in the process. Instead, functionally active mitochondria are often contained in apoptotic bodies,
which are rapidly recognized, phagocytized, and digested by macrophages or by adjacent epithelial cells.
The period of DNA fragmentation (the F phase in the Figure) can be used to divide the temporal series of events involved in PCD.[7] During the D1 phase of PCD, the
cell undergoes epigenetic reprogramming in which certain genes that were previously expressed are now repressed, while other genes that were previously repressed
are now expressed.[8-10] These epigenetic changes result in the activation of double-stranded DNA fragmentation during the F phase. During this F phase, the nuclear
morphology changes (ie, nuclear margination of chromatin, followed by nuclear condensation), although the plasma and lysosomal membranes are still intact and the
mitochondria are still functional.
Subsequent to the F phase, proteases are activated during the D2 phase, including the interleukin-1 beta-converting enzyme (ICE)-like proteases that hydrolyzes poly
(ADP-ribose) polymerase.[11] In addition, other ICE-like proteases[12] degrade the lamins in the nuclear membrane, and the nucleus itself undergoes fragmentation.
Plasma membrane blebbing and eventual cellular fragmentation into clusters of membrane-bound apoptotic bodies occur subsequent to the nuclear fragmentation. Once
formed, these apoptotic bodies are rapidly recognized, phagocytized, and digested by macrophages or by adjacent epithelial cells.
The overall cell cycle that controls cell number is thus composed of a multicompartment system in which the cell has multiple capabilities (Figure). The cell can be (1)
metabolically active but not undergoing either proliferation or death (G0 cell); (2) undergoing cell proliferation (G0 -> G1 -> S -> G2 -> mitosis), or (3) undergoing cell
death by either the programmed pathway (D1 -> F -> D2 apoptotic cellular fragmentation) or the nonprogrammed (necrotic) pathway. Cells in any phase (G0, G1, S,
or G2 or mitosis) can be induced to enter the PCD pathway. Indeed, proliferating cells characteristically undergo programmed (apoptotic) death if their progression
through the cell cycle is sufficiently perturbed.[13]
Types of Genes Involved in PCD
Based on the use of protein synthesis inhibitors, it is clear that the enzymatic machinery for completing PCD is already present within cells. However, numerous studies
have demonstrated that the signal transduction needed to activate this pre-existing death machinery sometimes requires new protein synthesis. This suggests that there
are three types of gene products involved in the process of PCD. The first are those involved in generating the signal transduction for activation of the death process in
healthy, undamaged cells (sometimes referred to as physiological cell death) (Table). These type-I gene products often are highly contextual with regard to the
particular cell type (ie, during differentiation of the particular cell type, specific gene products are selected for such regulatory roles). Thus, the same gene product can
have both the ability to stimulate cell proliferation and PCD depending on the differentiation status of the cell. For example, transforming growth factor-beta (TGFbeta1) is a cell-type-specific type-I gene that can stimulate proliferation of mesenchymal cells while stimulating the death of certain epithelial cells.[14] Genetic changes
that induce loss of function of these type-I genes allow the affected cells to be resistant to specific induction of physiological cell death. For example, glucocorticoid
activates programmed death in certain thymus cells. If such responsive cells undergo loss of function mutations in their glucocorticoid receptor, the variant cells are
resistant to glucocorticoid-induced programmed death.
The second type of PCD genes encodes proteins involved in determining the sensitivity to activation of PCD that are initiated by pathological damage to the cell (eg,
radiation, viral infection, chemotherapy). This second type of PCD gene includes p53 and bcl-2. The functional expression of the gene p53 increases the sensitivity of
the expressing cells to activation of programmed death induced by a wide variety of damaging agents (Table). Genetic alteration leading to the loss of function of this
type-II gene decreases the sensitivity of the affected cells to pathological (damage-induced) PCD (eg, from radiation, chemotherapy, viral infection). In contrast, bcl-2
is a gene whose functional expression decreases the sensitivity of the expressing cells to activation of PCD induced by the same types of damaging agents. Thus, genetic
alterations leading to the loss of function of this type of gene increases the sensitivity of the affected cells to pathological PCD.
Unlike the first two types of programmed death genes that encode proteins involved in the signal-transduction-induced activation of PCD, a third group of genes
encode proteins that are the actual machinery needed for the process of cell death itself (Table). Genetic alteration in this third type of gene that results in loss of
function would prevent the cell's ability to undergo PCD. This genotype would be reflected in a cellular phenotype that would be universally resistant to PCD induced
by all treatment, both physiological and pathological. Such a universally resistant genotype would provide a great selective advantage to any cell so affected. There are
cells that are resistant to hypoxia, radiation, chemotherapy, or growth factor deprivation. These observations suggest that the basic machinery to complete PCD also
must be required for completion of cell proliferation. Thus, any genetic alteration in the type III PCD genes that inactivate a critical component of the machinery of PCD
may lead to a sterile cell type unable to proliferate, and this genotype would be eliminated (ie, it is a lethal genotype).
Role of Cell Proliferation in PCD
Various independent investigators have demonstrated that proliferating cells can be induced to undergo PCD at any stage of the proliferative cell cycle (G1, S, G2, M).
Entrance into and progression through the proliferative cell cycle is not absolutely required, however, for PCD. For example, immature thymocytes can undergo PCD
when they are proliferatively quiescent (ie, out of cycle in G0) without any attempt to enter even the earliest part of G1.[15-17] Likewise, androgen-dependent prostatic
glandular cells undergo PCD following androgen ablation in G0 without entrance into the cell cycle.[7,18] Like normal prostate glandular cells, androgen-dependent
prostatic cancer cells are induced to undergo PCD by androgen ablation, and this PCD also does not require progression into the S phase.[19]
This induction of PCD is the basis for the initial response to androgen ablation therapy that is seen in the majority of patients with metastatic prostatic cancer. Androgen
ablation does not induce the programmed death of androgen-independent prostatic cancer cells. However, PCD can be induced in androgen-independent prostatic
cancer cells in G0 if the intracellular calcium is chronically sustained at twofold to threefold above baseline.[20,21]
These combined results demonstrate that PCD can be activated in both proliferation-independent (ie, G0 or interphase death) and proliferation-dependent manners and
that proliferation-dependent activation of cell death can occur at any stage of the proliferative cell cycle (Figure). In addition, although cells can undergo PCD without
entrance into and progression through the S phase of the cell cycle, the double-stranded DNA fragmentation induced during PCD can activate a futile process of DNA
repair.[7] Such DNA repair is not required for PCD but can lead to erroneous conclusions when using nucleotide precursor incorporation to evaluate the proliferative
status of the cell undergoing PCD.[7]
PCD in the Prostate Induced by Androgen Withdrawal
In the prostate, PCD is induced in the glandular epithelium following androgen deprivation. This system will be described in some detail to better illustrate the
morphological, genetic, and biochemical changes that occur when a group of cells undergoes PCD in response to a specific therapy. The programmed death induced in
the prostate by androgen withdrawal is cell-type specific. Only the prostatic glandular epithelial cells and not the basal epithelial or stromal cells are androgen
independent and thus undergo PCD following castration.[22] These glandular cells constitute approximately 80% of the total cells in the ventral prostate of an intact
adult rat and approximately 70% of these glandular cells die by seven days following castration.[22] Using the ventral prostate of the rat as a model system, the
temporal sequence of events involved in the PCD pathway induced by androgen ablation has begun to be defined. After castration of these animals, the serum
testosterone level drops to 1.2% of intact controls within six hours.[6] By 12 to 24 hours following castration, the level of prostatic dihydrotestosterone (DHT), the
active intracellular androgen in prostatic cells, is only 5% of intact controls. This lowering of prostatic DHT leads to changes in nuclear androgen function, and at 12
hours postcastration, androgen receptors are no longer retained in isolated ventral prostatic nuclei.[6] These nuclear receptor changes result in a major epigenetic
reprogramming within the nonproliferating glandular cell resulting in the activation or D1 phase of the programmed death process (Figure).
During this D1-activation phase, certain genes that were actively transcribed and translated before castration are rapidly turned off, including the C3 subunit of the
prostatein gene (the major secretory protein of the glandular cells), ornithine decarboxylase, histone H4, p53, and glucose-related protein.[8] Other genes that were not
actively transcribed and translated become rapidly induced. These genes include c-myc,[23] glutathione S-transferase subunit Yb1,[24] testosterone-repressed
prostatic message (TRPM-2),[25] H-ras,[8] calmodulin,[8] TGF-beta1,[26] and tissue transglutaminase.[8] TRPM-2,[27] calmodulin,[28] and tissue transglutaminase
[29] have been demonstrated to be induced in a variety of other cell types undergoing PCD. Several of these genes (c-myc, H-ras) previously have been demonstrated
to be involved in cell proliferation. Comparisons of levels of expression of these genes during castration-induced regression and subsequent androgen-induced
proliferative regrowth demonstrated enhanced expression of c-myc, H-ras, and tissue transglutaminase in both prostatic cell death and proliferation.[8]
The result of this epigenetic reprogramming is that during the D1-activation phase of the PCD process, there is a change in the profile of proteins that are synthesized,
which is coupled with an inhibition of glandular cell proliferation,[30] a decrease in polyamine levels,[31] and an increase in intracellular-free Ca2+ levels.[32,33] The
increase in intracellular free Ca2+ that occurs following castration is derived from the extracellular pool.[32] The mechanism for this induced elevation in intracellularfree Ca2+ is not fully known. There are indications that enhanced expression of TGF-beta1 mRNA and protein[26] as well as the receptor for TGF-beta1[26]
following castration are somehow involved in the elevation of intracellular free Ca2+.[33]
Once the intracellular Ca2+ reaches a critical level, Ca2+-Mg2+-dependent endonucleases present within the nuclei of the prostatic glandular cells are enzymatically
activated.[26] Normally, polyamines[34] and histone H1 maintain DNA in a compacted form that is not an efficient substrate for Ca2+-Mg2+-dependent
endonucleases. However, during the D1-activation phase there are decreases in levels of polyamines[31] and the nuclear content of histone H1[35] resulting in changes
in the genomic DNA conformation and an opening up of the linker regions between nucleosomes. This enhances the accessibility of the linker DNA to the activated
Ca2+-Mg2+-dependent endonuclease. Once this occurs, DNA fragmentation begins at sites located between nucleosomal units (the F phase of the PCD process)
(Figure) and cell death is no longer reversible.
During the F phase, the nuclear morphology changes, and there is chromatin condensation with nuclear margination even though the plasma and lysosomal membranes
are still intact and mitochondria are still functional.[22] During the subsequent portion of the death process, termed the D2 phase, the Ca2+-dependent tissue
transglutaminase actively crosslinks various membrane proteins (J.T.I., unpublished data, 1993), with resultant cell surface blebbing, nuclear disintegration, and
eventually cellular fragmentation into clusters of membrane-bound apoptotic bodies. Plasma membrane changes within these apoptotic bodies appear to be recognized
by macrophages and neighboring epithelial cells; this recognition leads to rapid phagocytosis of the apoptotic bodies.[22,36,37] Thus, within seven to 10 days following
castration, approximately 80% of the glandular cells die and are eliminated from the rat prostate.
PCD Induced by Damaging Agents
Programmed death of prostatic glandular cells following androgen ablation is an extreme case of physiological elimination of a group of cells. Normally in the adult,
androgen levels are regulated such that such catastrophic elimination of prostatic cells does not occur. A low level (2% per day) of the prostatic glandular cells do
undergo PCD, however, even in the presence of adequate androgen.[38] Presumably, this is due to the accumulation of a critical amount of damage to the cells
secondary to their secretory function. These glandular cells produce and secrete large amounts of protease and polyamines,[39] both of which can be damaging to
cells. If a critical amount of such endogenously generated damage is accumulated, the PCD pathway is activated. This has been demonstrated by a variety of
pathological conditions, including physical agents (such as radiation, physical trauma, cold shock, and chemicals) and infectious agents (such as viruses). For example,
when exposed to cold but not freezing temperatures for one to two hours, nondividing cells undergo PCD when rewarmed to 37°C.[40] With respect to ionizing radiation-induced damage, lymphocytes are the most sensitive cells in the body. Resting, nonproliferating lymphocytes rapidly undergo PCD following appropriate
doses of ionizing radiation.[41] Viral infection also can induce PCD in various host target cells.[42,43] These results suggest that normal cells activate their PCD
pathway when they have accumulated a critical amount of injury that cannot be adequately repaired.
PCD has been shown to occur spontaneously in a wide variety of tumor types. Apoptosis has been observed in most solid tumors including cancers of the prostate,
[44] breast,[45] pancreas,[46] skin,[47] and colon,[48] as well as in several types of leukemia[49,50] and non-Hodgkin's lymphoma.[51] Many of the commonly used
chemotherapeutic agents also have been shown to cause apoptosis in chemosensitive cells. The induction of apoptosis in lymphoid tissue by glucocorticoids has been
most intensively studied. In 1980, Wyllie[5] was the first to demonstrate the induction of apoptosis in immature rat thymocytes with dexamethasone treatment. Early
studies in this system helped to define the classic morphological and biochemical features of apoptosis. Since these early studies, the list of agents that induce apoptosis
has grown and includes alkylating agents (eg, chlorambucil and BCNU), antimetabolites (eg, fluorouracil and Ara-C), topoisomerase I and II inhibitors (eg,
camptothecin and etoposide), and hormonal manipulation (eg, antiestrogens and androgen withdrawal).[52,53]
Previous studies have demonstrated that when the DNA of a proliferating cell is sufficiently damaged with a variety of chemicals, such as alkylating agents or mitogenic
agents, the cell arrests in G2 and undergoes PCD.[54] Likewise, agents such as 5-fluorodeoxyuridine that inhibit the progression through the S phase of proliferative
cell cycle induce PCD.[55] Mimosine, an agent that arrests cells in the G1 phase of the proliferative cell cycle,[56] also can induce PCD (unpublished data, J.T.I.,
1993). The mechanism that enables the cell to "sense" such cellular arrest during the proliferative cell cycle and activate PCD is not understood. One possible
explanation for the cytotoxic effects of cell cycle arrest is that these agents dissociate the normally integrated cell cycle events that lead to "unbalanced growth" and
eventually programmed death of the cells.[13] Regardless of the mechanism, these results clearly demonstrate that PCD can be activated not only in cells in G but also
in cells in the various part of the proliferative cell cycle (Figure).
Modulation of Responsiveness to PCD
Tumor cell resistance to chemotherapeutic agents has emerged as an obstacle to the development of effective therapies. Mechanisms of drug resistance include drug
target amplification (methotrexate), enhanced repair of DNA damage (alkylating agents), increased drug metabolism, or altered drug accumulation. Mechanisms for
tumor resistance to multiple drugs include the multidrug-resistant phenotype conferred by increases in the multidrug-resistant (MDR-1) gene product encoding a plasma
membrane drug efflux pump; by enhanced p450 activity; by mutations in topoisomerases; and by alterations in the redox detoxifying actions of glutathione.[57] Until
recently, efforts to understand chemoresistance have been focused on modulation of the drug/target interaction either by changes in the amount of drug present within a
cell or by alterations in the amount or structure of the drug target.[58] However, a more important aspect of resistance may have less to do with the drug/target
interaction and more to do with how cells sense the ensuing damage and respond to it.[57] Major questions remain unanswered: How do cells sense damage, how do
they activate the PCD pathway, and how do various agents such as oncoproteins modify this sensing mechanism? Modulation of responsiveness to PCD has emerged
as a new type of treatment resistance, and one that is shared by a variety of tumor types.
Susceptibility to activation of the PCD pathway varies among cell types. For instance, within the prostate, glandular epithelial cells readily undergo apoptosis (seven to
10 days) on androgen withdrawal, while neighboring stromal and basal cells are unaffected. Likewise, thymocytes rapidly apoptose when irradiated, while similar doses
of radiation have no lethal effect on other cell types such as fibroblasts.[41] It is currently unknown what triggers PCD in one cell type and not another in response to
the same agent. However, it appears that cells, even within the same tumor, differ in their threshold for induction of apoptosis, whether it be induced by damaging
agents or by environmental changes such as growth factor deprivation. This threshold for activation of PCD has been shown to be modulated by a variety of genetic
changes. For instance, loss of function of genes such as p53 or overexpression of other genes such as bcl-2 would increase the threshold for activation of PCD. Thus,
cancer cells harboring these changes would become more resistant to cell-damaging agents and also would be more likely to survive removal of growth/survival factors.
New therapeutic strategies aimed at decreasing the threshold for activation of PCD (eg, by inhibiting the bcl-2 protein function) are currently under development, as
well as agents capable of directly triggering the PCD cascade.
Conclusions
Several chemotherapeutic agents kill cancer cells by activation of the PCD pathway. However, in clinical practice, the majority of human tumors, especially solid
tumors, remain resistant to most therapeutic agents, even when used in combination. It is becoming increasingly clear that the most important determinant of tumor
resistance may be a generalized resistance to induction of PCD, rather than resistance based on specific alterations in the drug/target interaction. Alterations in a variety
of oncogenes and tumor suppressor genes have been shown to modulate responsiveness to PCD induction by chemotherapeutic agents and radiation. Additional work
is needed to delineate the function of these modulatory proteins and to define the cellular machinery involved in the PCD pathway itself. Further understanding of these
cellular pathways should help in developing new strategies for overcoming cancer resistance and may yield more effective therapies in the future.
Appreciation is expressed to Barbara A. Lee for assistance in preparing this manuscript.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
Isaacs JT. Role of programmed cell death in carcinogenesis. Environ Health Perspect. 1993;101(suppl 5):27-33.
Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1990;68:251-306.
Tomei LD, Cope FO, eds. Apoptosis: The Molecular Basis of Cell Death. Plainville, NY: Cold Spring Harbor Laboratory Press; 1991.
Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284:555-556.
Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 1988;122:552-562.
Berges RS, Furuya Y, Remington L, et al. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells
induced by androgen ablation. Proc Natl Acad Sci U S A. 1993;90:8910-8914.
Furuya Y, Isaacs JT. Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen
manipulation. Endocrinology. 1993;133:2660-2666.
Smeyne RJ, Vendrell M, Hayward M, et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature. 1993;363:166-169.
Deng G, Podack ER. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the
protooncogene bcl-2. Proc Natl Acad Sci U S A. 1993;90:2189-2193.
Lazebnik YA, Kaufman SH, Desnoyers S, et al. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994;371:346347.
Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature.
1995;376:37-43.
Kung AL, Zetterberg A, Sherwood SW, et al. Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation. Cancer Res. 1990;50:73077317.
Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta1 on proliferation and death of rat prostatic cells. Endocrinology.
1990;127:2963-2968.
Walker PR, Smith C, Youdale T, et al. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res. 1991;51:1078-1085.
Bruno S, Lassota W, Giaretti W, et al. Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to G0 cells and is
prevented in inhibitors of proteases. Oncol Res. 1992;4:29-35.
Evans DL, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res.
1993;53:2133-2139.
Furuya Y, Lin XS, Walsh JC, et al. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell
cycle or p53 induction. Endocrinology. 1995;136:1898-1906.
Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res.
1990;50:3748-3753.
Martikainen P, Kyprianou N, Tucker RW, et al. Programmed cell death of nonproliferating androgen-independent prostatic cancer cell. Cancer Res.
1991;51:4693-4700.
Furuya Y, Lundmo P, Short AD, et al. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgenindependent prostatic
cancer cells induced by thapsigargin. Cancer Res. 1994;54:61676175.
English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following
castration. Prostate. 1989;15:233-250.
Quarmby VE, Beckman WC Jr, Wilson EM, et al. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol Endocrinol.
1987;1:865-874.
Chang CS, Saltzman AG, Sorensen NS, et al. Identification of glutathione S-transferase Yb1 mRNA as the androgen-repressed mRNA by cDNA cloning and
sequence analysis. J Biol Chem. 1987;262:11901-11903.
Montpetit ML, Lawless KR, Tenniswood M. Androgen-repressed messages in the rat ventral prostate. Prostate. 1986;8:25-36.
Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens.
Endocrinology. 1988;123:2124-2131.
Buttyan R, Olsson CA, Pintar J, et al. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol. 1989;9:3473-3481.
Dowd DR, MacDonald PN, Komm BS, et al. Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated
apoptosis. J Biol Chem. 1991;266:18423-18436.
Fesus L, Thomazy V, Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett. 1987;224:104-108.
Kyprianou N, Isaacs JT. Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate. 1987;10:313-324.
Pegg AE, Lockwood DH, Williams-Ashman HG. Concentrations of putrescine and polyamines and their enzymatic synthesis during androgen-induced prostatic
growth. Biochem J. 1970;117:17.
Kyprianou N, English HF, Isaacs JT. Activation of a Ca2- Mg2+dependent endonuclease as an early event in castrationinduced prostatic cell death. Prostate.
1988;13:103117.
33. Martikainen P, Isaacs JT. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate. 1990;17:175187.
34. Snyder RD. Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem J. 1989;260:697-704.
35. Chung LWK, Coffey DS. Biochemical characterization of prostate nuclei I. Androgen-induced changes in nuclear proteins. Biochem Biophys Acta.
1971;247:570.
36. Kerr JFR, Searle J. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch B Cell Pathol. 1973;13:87.
37. Savill J, Dransfield I, Hogg N, et al. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature. 1990;343:170-173.
38. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5:545-558.
39. Isaacs JT. Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate. 1983;4:351-366.
40. Soloff BL, Nagle WA, Moss AJ Jr, et al. Apoptosis induced by cold shock in vitro is dependent on cell growth phase. Biochem Biophys Res Comm.
1987;145:876-883.
41. Sellins KS, Cohen JJ. Gene induction by g-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1987;139:3199-3206.
42. Lai Fatt RB, Mak S. Mapping of an adenovirus function involved in the inhibition of DNA degradation. J Virol. 1982;42:969-977.
43. Caillet-Fauquet P, Perros M, Brandenburger A, et al. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding nonstructural proteins. EMBO J. 1990;9:2989-2995.
44. Szepeshazi K, Korkut E, Szende B, et al. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75. Prostate.
1991;18:255-270.
45. Mendelsohn ML. Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. II. Growth and survival of cells labelled with
tritiated thymidine. J Natl Cancer Inst. 1990;25:485-500.
46. Szepeshazi K, Lapis K, Schally AV. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5fluorouracil on pancreatic cancer in hamsters. Int J Cancer. 1991;49:260-266.
47. el-Labban NG, Osorio-Herrera E. Apoptotic bodies and abnormally dividing epithelial cells in squamous cell carcinoma. Histopathology. 1986;10:921-931.
48. Potten CS, Li YQ, O'Connor PJ, et al. A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects
of carcinogens in the murine large bowel. Carcinogenesis. 1992;13:2305-2312.
49. Baxter GD, Collins RJ, Harmon BV, et al. Cell death by apoptosis in acute leukaemia. J Pathol. 1989;158:123-129.
50. McConkey DJ, Aguilar-Santelises M, Hartzell P, et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol. 1991;146:10721076.
51. del Vecchio MT, Leoncini L, Buerki K, et al. Diffuse centrocytic and/or centroblastic malignant non-Hodgkin's lymphomas: comparison of mitotic and pyknotic
(apoptotic) indices. Int J Cancer. 1991;47:38-43.
52. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121-139.
53. Schwartzman RA, Cidlowski JA. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrinol Rev. 1993;14:133-151.
54. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem
Pharmacol. 1990;40:2353-2362.
55. Kyprianou N, Isaacs JT. "Thymineless" death in androgen-independent prostatic cancer cells. Biochem Biophys Res Comm. 1989;165:73-81.
56. Lalande M. A reversible arrest point in the late G1 phase of the mammalian cell cycle. Exp Cell Res. 1990;186:332-339.
57. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78:539-542.
58. Hickman JA, Beere HM, Wood AC, et al. Mechanisms of cytotoxicity caused by antitumour drugs. Toxicol Lett. 1992;64/65:553-561.